Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer

L. Di Lauro, F. Belli, M. G. Arena, S. Carpano, G. Paoletti, D. Giannarelli, M. Lopez

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Docetaxel is a new agent with activity in metastatic gastric cancer. This phase II study was designed to evaluate the activity and safety of an epirubicin, cisplatin and docetaxel combination in patients with this disease. Patients and methods: Forty-six patients with gastric adenocarcinoma with measurable distant metastasis were eligible for the study. Patients received epirubicin 50 mg/m2 and docetaxel 60 mg/m2, on day 1, and cisplatin 60 mg/m2 on day 2. Granulocyte colony-stimulating factor 300 μg/day subcutaneously was given on days 5 and 6. Cycles were repeated every 3 weeks for a maximum of eight courses. Results: All patients were evaluable for response and toxicity. Two complete and 21 partial responses were observed, with an overall response rate of 50% [95% confidence interval (CI) 36% to 64%]. Stable disease was observed in 13 patients (28%) and progressive disease in 10 patients (22%). The median time to progression was 6 months (95% CI 5 - 7) and the median overall survival was 11.2 months (95% CI 8.5 - 13.9). Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 46%, 7% and 13% of patients, respectively. There were five episodes of febrile neutropenia in four patients. Other grade 3 toxicities included mucositis in three patients (6.5%), vomiting in four patients (8.7%) and diarrhea in one patient (2%). There were no cardiac toxicity, severe neurotoxicity or treatment-related deaths. Conclusions: The epirubicin, cisplatin and docetaxel combination is an active and well tolerated novel chemotherapy regimen for treating metastatic gastric cancer and deserves further evaluation in randomized studies.

Original languageEnglish
Pages (from-to)1498-1502
Number of pages5
JournalAnnals of Oncology
Volume16
Issue number9
DOIs
Publication statusPublished - Sep 2005

Fingerprint

docetaxel
Epirubicin
Cisplatin
Stomach Neoplasms
Therapeutics
Confidence Intervals

Keywords

  • Cisplatin
  • Docetaxel
  • Epirubicin
  • Metastatic gastric cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Di Lauro, L., Belli, F., Arena, M. G., Carpano, S., Paoletti, G., Giannarelli, D., & Lopez, M. (2005). Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. Annals of Oncology, 16(9), 1498-1502. https://doi.org/10.1093/annonc/mdi281

Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. / Di Lauro, L.; Belli, F.; Arena, M. G.; Carpano, S.; Paoletti, G.; Giannarelli, D.; Lopez, M.

In: Annals of Oncology, Vol. 16, No. 9, 09.2005, p. 1498-1502.

Research output: Contribution to journalArticle

Di Lauro, L, Belli, F, Arena, MG, Carpano, S, Paoletti, G, Giannarelli, D & Lopez, M 2005, 'Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer', Annals of Oncology, vol. 16, no. 9, pp. 1498-1502. https://doi.org/10.1093/annonc/mdi281
Di Lauro, L. ; Belli, F. ; Arena, M. G. ; Carpano, S. ; Paoletti, G. ; Giannarelli, D. ; Lopez, M. / Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. In: Annals of Oncology. 2005 ; Vol. 16, No. 9. pp. 1498-1502.
@article{65c0c8448f154f44bacf07092113b493,
title = "Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer",
abstract = "Background: Docetaxel is a new agent with activity in metastatic gastric cancer. This phase II study was designed to evaluate the activity and safety of an epirubicin, cisplatin and docetaxel combination in patients with this disease. Patients and methods: Forty-six patients with gastric adenocarcinoma with measurable distant metastasis were eligible for the study. Patients received epirubicin 50 mg/m2 and docetaxel 60 mg/m2, on day 1, and cisplatin 60 mg/m2 on day 2. Granulocyte colony-stimulating factor 300 μg/day subcutaneously was given on days 5 and 6. Cycles were repeated every 3 weeks for a maximum of eight courses. Results: All patients were evaluable for response and toxicity. Two complete and 21 partial responses were observed, with an overall response rate of 50{\%} [95{\%} confidence interval (CI) 36{\%} to 64{\%}]. Stable disease was observed in 13 patients (28{\%}) and progressive disease in 10 patients (22{\%}). The median time to progression was 6 months (95{\%} CI 5 - 7) and the median overall survival was 11.2 months (95{\%} CI 8.5 - 13.9). Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 46{\%}, 7{\%} and 13{\%} of patients, respectively. There were five episodes of febrile neutropenia in four patients. Other grade 3 toxicities included mucositis in three patients (6.5{\%}), vomiting in four patients (8.7{\%}) and diarrhea in one patient (2{\%}). There were no cardiac toxicity, severe neurotoxicity or treatment-related deaths. Conclusions: The epirubicin, cisplatin and docetaxel combination is an active and well tolerated novel chemotherapy regimen for treating metastatic gastric cancer and deserves further evaluation in randomized studies.",
keywords = "Cisplatin, Docetaxel, Epirubicin, Metastatic gastric cancer",
author = "{Di Lauro}, L. and F. Belli and Arena, {M. G.} and S. Carpano and G. Paoletti and D. Giannarelli and M. Lopez",
year = "2005",
month = "9",
doi = "10.1093/annonc/mdi281",
language = "English",
volume = "16",
pages = "1498--1502",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "9",

}

TY - JOUR

T1 - Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer

AU - Di Lauro, L.

AU - Belli, F.

AU - Arena, M. G.

AU - Carpano, S.

AU - Paoletti, G.

AU - Giannarelli, D.

AU - Lopez, M.

PY - 2005/9

Y1 - 2005/9

N2 - Background: Docetaxel is a new agent with activity in metastatic gastric cancer. This phase II study was designed to evaluate the activity and safety of an epirubicin, cisplatin and docetaxel combination in patients with this disease. Patients and methods: Forty-six patients with gastric adenocarcinoma with measurable distant metastasis were eligible for the study. Patients received epirubicin 50 mg/m2 and docetaxel 60 mg/m2, on day 1, and cisplatin 60 mg/m2 on day 2. Granulocyte colony-stimulating factor 300 μg/day subcutaneously was given on days 5 and 6. Cycles were repeated every 3 weeks for a maximum of eight courses. Results: All patients were evaluable for response and toxicity. Two complete and 21 partial responses were observed, with an overall response rate of 50% [95% confidence interval (CI) 36% to 64%]. Stable disease was observed in 13 patients (28%) and progressive disease in 10 patients (22%). The median time to progression was 6 months (95% CI 5 - 7) and the median overall survival was 11.2 months (95% CI 8.5 - 13.9). Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 46%, 7% and 13% of patients, respectively. There were five episodes of febrile neutropenia in four patients. Other grade 3 toxicities included mucositis in three patients (6.5%), vomiting in four patients (8.7%) and diarrhea in one patient (2%). There were no cardiac toxicity, severe neurotoxicity or treatment-related deaths. Conclusions: The epirubicin, cisplatin and docetaxel combination is an active and well tolerated novel chemotherapy regimen for treating metastatic gastric cancer and deserves further evaluation in randomized studies.

AB - Background: Docetaxel is a new agent with activity in metastatic gastric cancer. This phase II study was designed to evaluate the activity and safety of an epirubicin, cisplatin and docetaxel combination in patients with this disease. Patients and methods: Forty-six patients with gastric adenocarcinoma with measurable distant metastasis were eligible for the study. Patients received epirubicin 50 mg/m2 and docetaxel 60 mg/m2, on day 1, and cisplatin 60 mg/m2 on day 2. Granulocyte colony-stimulating factor 300 μg/day subcutaneously was given on days 5 and 6. Cycles were repeated every 3 weeks for a maximum of eight courses. Results: All patients were evaluable for response and toxicity. Two complete and 21 partial responses were observed, with an overall response rate of 50% [95% confidence interval (CI) 36% to 64%]. Stable disease was observed in 13 patients (28%) and progressive disease in 10 patients (22%). The median time to progression was 6 months (95% CI 5 - 7) and the median overall survival was 11.2 months (95% CI 8.5 - 13.9). Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 46%, 7% and 13% of patients, respectively. There were five episodes of febrile neutropenia in four patients. Other grade 3 toxicities included mucositis in three patients (6.5%), vomiting in four patients (8.7%) and diarrhea in one patient (2%). There were no cardiac toxicity, severe neurotoxicity or treatment-related deaths. Conclusions: The epirubicin, cisplatin and docetaxel combination is an active and well tolerated novel chemotherapy regimen for treating metastatic gastric cancer and deserves further evaluation in randomized studies.

KW - Cisplatin

KW - Docetaxel

KW - Epirubicin

KW - Metastatic gastric cancer

UR - http://www.scopus.com/inward/record.url?scp=24044537615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044537615&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi281

DO - 10.1093/annonc/mdi281

M3 - Article

VL - 16

SP - 1498

EP - 1502

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -